Shaheer Khan1, Richard D Carvajal2,3. 1. Department of Hematology and Oncology, Columbia University Irving Medical Center, 177 Ft. Washington Avenue, MHB 6GN-435, New York, NY, 10032, USA. sk4488@cumc.columbia.edu. 2. Department of Hematology and Oncology, Columbia University Irving Medical Center, 177 Ft. Washington Avenue, MHB 6GN-435, New York, NY, 10032, USA. 3. Herbert Irving Comprehensive Cancer Center, New York, NY, USA.
Abstract
PURPOSE OF REVIEW: Uveal melanoma is a distinct subtype of melanoma characterized by a unique biology and divergent response to immune therapies. In this review, we will discuss our current understanding of the pathophysiology of uveal melanoma, systemic treatment options for advanced disease, and potential future therapeutic directions. RECENT FINDINGS: Although treatment with single-agent checkpoint blockade has been generally disappointing, the results of combined checkpoint blockade are modestly more promising. Several alternative systemic therapeutic approaches have been or are currently being investigated, including two agents that have been taken into registration-intent clinical trials: tebentafusp, a T cell redirecting agent, and IDE196, an oral protein kinase C inhibitor. Treatment of advanced uveal melanoma remains challenging, however, encouraging results from novel agents offer hope for improvement in the near future.
PURPOSE OF REVIEW: Uveal melanoma is a distinct subtype of melanoma characterized by a unique biology and divergent response to immune therapies. In this review, we will discuss our current understanding of the pathophysiology of uveal melanoma, systemic treatment options for advanced disease, and potential future therapeutic directions. RECENT FINDINGS: Although treatment with single-agent checkpoint blockade has been generally disappointing, the results of combined checkpoint blockade are modestly more promising. Several alternative systemic therapeutic approaches have been or are currently being investigated, including two agents that have been taken into registration-intent clinical trials: tebentafusp, a T cell redirecting agent, and IDE196, an oral protein kinase C inhibitor. Treatment of advanced uveal melanoma remains challenging, however, encouraging results from novel agents offer hope for improvement in the near future.
Authors: Chiara R Dart; Nabanita Mukherjee; Carol M Amato; Anabel Goulding; Morgan MacBeth; Robert Van Gulick; Kasey L Couts; James R Lambert; David A Norris; William A Robinson; Yiqun G Shellman Journal: Pharmaceuticals (Basel) Date: 2021-07-30